Healthcare services group Uniphar said its earnings per share for 2025 came in ahead of its expectations, adding that it is confident of reaching its €200m EBITDA target by 2028.
Its shares saw strong gains in Dublin trade today.
In a trading update for the year to the end of December, Uniphar said the business reported adjusted EPS growth of about 21% last year.
It said this came on the back of a strong trading performance with about 9% organic gross profit growth, lower finance costs and accretion from the €35m share buy-back programme.
The group said it continues to maintain a strong liquidity position.
Looking ahead, Uniphar said it is well positioned to deliver organic gross profit growth across all divisions.
It also said that merger and acquisitions continue to play an important role in Uniphar's growth strategy.
"The group maintains a disciplined approach to capital allocation, while managing an active pipeline of acquisition opportunities to further enhance the group's growth potential," it added.
Ger Rabbette, Uniphar's group chief executive, said that 2025 was another great year for Uniphar, with all of its divisions contributing to the fastest rate of organic gross profit growth since IPO.
"This underscores the positive impact that our strategy is having on our ability to scale organically. We remain confident of reaching our €200m EBITDA target by 2028, with at least 80% of our growth being organic," the CEO added.
